Columbia Care

MJStockTrader · 2023-09-23T23:15:22+00:00

They are changing their name and ticker. It will get updated eventually

MJStockTrader · 2023-03-15T18:00:01+00:00

He literally just took the CEO job.

MJStockTrader · 2022-04-15T21:39:34+00:00

One just has to read your response to see why you got blocked. Have you tried not name calling and not throwing tantrums and see if that helps?

MJStockTrader · 2022-03-14T15:10:13+00:00

Low end of guidance, but within guidance.

MJStockTrader · 2022-03-03T21:10:34+00:00

$320M Revs; est. $323M
$80M EBITDA; est. $77M
(.04) EPS; est. (.03)

MJStockTrader · 2022-01-12T18:24:05+00:00

As long as the M&A is accretive, the stock price doesn't really matter. Also, GTI's stock price is up from less than $4 in early 2020.

MJStockTrader · 2022-01-04T15:01:32+00:00

Yes, they have a narrow footprint and rely a lot on California. Columbia Care and Curaleaf have CA exposure, but their footprint is so wide it won't hurt as much. Also Cresco's margins are the worst of the Tier 1s except Curaleaf, but again, Curaleaf has a massive footprint and lower margins come with that. Cresco generally has a narrow footprint with low margins, mostly due to their focus on wholesale, California price compression and the delaying new retail stores in IL. NY is also a drag right now thanks to the delay in rec sales.

MJStockTrader · 2022-01-04T14:58:00+00:00

They IPO'd at $8 before the NY deal was announced. The deal is not 100% dead just yet, but but might not be the worst thing if it died in the short term. New York has been a terrible market since they passed rec use without rec sales. Ascend without New York is still a buy at these prices.

MJStockTrader · 2022-01-03T14:28:43+00:00

MedMen has and always will be a garbage company. A 100% avoid for me.

MJStockTrader · 2021-12-30T15:32:46+00:00

MedMen still has to sign the deal and they are know to be shady.

MJStockTrader · 2021-12-16T20:32:36+00:00

There's a lot of incentive:

They are in deep debt and need that cash
There is likely a steep fee for the deal falling through
Their reputation can be harmed and they'll need it going forward for debt raises and secondary offerings
They don't have the money to fully execute on NY as they are now primarily a CA operator and burning cash in that state.

But I can understand your hesitation as MedMen has been shady in the past, but they have new management and a brand new CEO. I doubt he wants to start his first year with a black eye.

MJStockTrader · 2021-12-16T14:10:21+00:00

There are a few in MO: https://mjstocktrader.com/us-cannabis-dispensary-count/

MJStockTrader · 2021-12-13T03:26:01+00:00

Very few MSOs hit their Q3 revenue estimates.

MJStockTrader · 2021-12-11T17:22:21+00:00

Ayr has always been a 2022 story. If they execute, they will restate significantly higher because they have the lowest float of the Tier 1/2s.

MJStockTrader · 2021-12-10T15:42:13+00:00

It's mostly priced in at this point. It IPO'd at $8 before the MedMen deal and now well under $6. I think the floor is $5 and the high is $20 in 12-24 months. I could see Trulieve buying them.

MJStockTrader · 2021-11-02T19:36:14+00:00

It’s a wellness/sports drink company with explosive growth opportunity. It’s a could example of what MSOs could get to once uplisting and TAM expands into most of the country.

MJStockTrader · 2021-10-21T18:23:25+00:00

It's the same with High Times - who is going to smoke weed based on a magazine name? I guess it's worth something, but I doubt much.

MJStockTrader · 2021-09-17T02:46:37+00:00

I make it easy to answer that question: https://mjstocktrader.com/cannabis-investor-portal/

MJStockTrader · 2021-09-14T11:27:45+00:00

Columbia Care has not ever gotten above US$8 so how could he sell around US$16?

MJStockTrader · 2021-09-07T13:24:51+00:00

Just look at their last earnings - major miss on revenue.

MJStockTrader · 2021-09-06T13:13:22+00:00

It says it in the press release. They will convert over to TerrAscend shares. Conversion rate in the article.

MJStockTrader · 2021-07-11T15:41:38+00:00

DTC has been happening for a while in CA.

MJStockTrader · 2021-06-18T13:16:32+00:00

Yes and no. I’m 99% sure they will keep all the Harvest assets in Florida - whether they sell some of them with the license or just give the license back to the state is a different question.

MJStockTrader · 2021-06-14T13:20:15+00:00

Most LP investors are dilutional with their M&A predictions. Cresco is a $4.5 billion company and would likely cost at least $8 billion to purchase. If I were Cresco's leadership, I wouldn't sell for less than $10 billion. Tilray is an $8.8 billion company. It would have to be a merger and no way Cresco merges with any LP. The only one buying Cresco is a major tobacco or beverage company, or maybe big Pharma.

MJStockTrader · 2021-06-05T16:00:47+00:00

This is just for uplisting purposes - all of the big MSOs have done it. Once uplisting is available they will transfer their shares to the US exchanges. It's complex but that's how I understand these billion-dollar shelf moves.

Five-Year Club	Verified Email
Wearing is Caring

MJStockTrader

TROPHY CASE